Assessment of the Key Drivers of Cost-Effectiveness in the Economic Modelling of Canagliflozin (CANA) Versus Glimepiride (GLIM) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting
Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.680
https://www.valueinhealthjournal.com/article/S1098-3015(13)02585-0/fulltext
Title :
Assessment of the Key Drivers of Cost-Effectiveness in the Economic Modelling of Canagliflozin (CANA) Versus Glimepiride (GLIM) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)02585-0&doi=10.1016/j.jval.2013.08.680
First page :
A441
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
656